tiprankstipranks
Artemis Medicare Services Ltd. (IN:ARTEMISMED)
:ARTEMISMED
India Market
Want to see IN:ARTEMISMED full AI Analyst Report?

Artemis Medicare Services Ltd. (ARTEMISMED) AI Stock Analysis

2 Followers

Top Page

IN:ARTEMISMED

Artemis Medicare Services Ltd.

(ARTEMISMED)

Select Model
Select Model
Select Model
Neutral 65 (OpenAI - 5.2)
Rating:65Neutral
Price Target:
₹285.00
▲(3.19% Upside)
Action:Reiterated
Date:05/11/26
The score is driven primarily by strong financial performance (growth, improving margins, and reduced leverage), tempered by inconsistent free-cash-flow conversion. Technicals are supportive but look overextended, while valuation is a notable headwind due to the high P/E and low dividend yield.
Positive Factors
Revenue & Profit Growth
Sustained multi-year revenue expansion and a marked rise in net margin signal durable demand and improving unit economics across the hospital network. This strengthens earnings power, funds reinvestment in services and capacity, and underpins medium-term growth resilience.
Negative Factors
Volatile Free Cash Flow & Weaker Cash Conversion
Uneven free cash flow and recent deterioration in cash conversion pose a structural risk to funding flexibility. If FCF remains volatile, it could constrain ability to deleverage, invest in growth or return capital, increasing sensitivity to operational disruptions over coming quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue & Profit Growth
Sustained multi-year revenue expansion and a marked rise in net margin signal durable demand and improving unit economics across the hospital network. This strengthens earnings power, funds reinvestment in services and capacity, and underpins medium-term growth resilience.
Read all positive factors

Artemis Medicare Services Ltd. (ARTEMISMED) vs. iShares MSCI India ETF (INDA)

Artemis Medicare Services Ltd. Business Overview & Revenue Model

Company Description
Artemis Medicare Services Limited manages and operates multi specialty hospitals in India and internationally. The company offers medical and surgical intervention; and inpatient and outpatient services. It also operates Artemis Hospital, a 541 be...
How the Company Makes Money
Artemis Medicare Services Ltd. generates revenue primarily through its medical services offered at its hospitals, including consultation fees, diagnostics, surgical procedures, inpatient and outpatient care, pharmacy sales, and laboratory testing....

Artemis Medicare Services Ltd. Financial Statement Overview

Summary
Strong multi-year revenue growth and materially improved profitability, alongside a healthier leverage profile by 2026. The main drag is cash-flow quality: free cash flow has been volatile and cash conversion weakened recently.
Income Statement
78
Positive
Balance Sheet
74
Positive
Cash Flow
58
Neutral
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue10.02B10.81B9.37B8.79B7.37B5.53B
Gross Profit2.27B2.15B2.23B1.78B1.04B954.40M
EBITDA1.67B1.88B1.52B1.25B1.01B713.53M
Net Income949.45M1.04B826.26M491.41M385.98M318.14M
Balance Sheet
Total Assets14.26B14.29B13.57B9.72B9.05B7.10B
Cash, Cash Equivalents and Short-Term Investments3.48B2.06B3.96B612.05M509.42M276.98M
Total Debt2.79B2.62B2.90B3.20B2.86B2.01B
Total Liabilities5.38B4.88B5.14B5.17B4.97B3.48B
Stockholders Equity8.83B9.35B8.38B4.48B4.03B3.59B
Cash Flow
Free Cash Flow136.32M321.88M524.65M363.01M-337.68M-573.20M
Operating Cash Flow804.83M1.37B1.46B1.09B1.13B515.80M
Investing Cash Flow-681.67M-1.19B-3.85B-891.04M-1.58B-1.08B
Financing Cash Flow-270.77M-265.64M2.67B-41.48M521.82M528.37M

Artemis Medicare Services Ltd. Technical Analysis

Technical Analysis Sentiment
Positive
Last Price276.20
Price Trends
50DMA
244.40
Positive
100DMA
243.70
Positive
200DMA
247.49
Positive
Market Momentum
MACD
10.93
Positive
RSI
59.17
Neutral
STOCH
65.84
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ARTEMISMED, the sentiment is Positive. The current price of 276.2 is above the 20-day moving average (MA) of 269.76, above the 50-day MA of 244.40, and above the 200-day MA of 247.49, indicating a bullish trend. The MACD of 10.93 indicates Positive momentum. The RSI at 59.17 is Neutral, neither overbought nor oversold. The STOCH value of 65.84 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:ARTEMISMED.

Artemis Medicare Services Ltd. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
72
Outperform
₹111.44B60.480.21%23.64%29.96%
71
Outperform
₹35.95B18.980.96%9.30%14.06%
67
Neutral
₹725.29B67.310.11%17.28%34.55%
65
Neutral
₹43.86B41.670.16%15.40%19.65%
56
Neutral
₹313.99B126.0428.65%-37.24%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
50
Neutral
₹18.59B48.080.59%5.01%618.23%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
IN:ARTEMISMED
Artemis Medicare Services Ltd.
274.60
-4.55
-1.63%
IN:FORTIS
Fortis Healthcare Ltd.
929.90
224.04
31.74%
IN:INDRAMEDCO
Indraprastha Medical Corporation Limited
380.55
-56.27
-12.88%
IN:KIMS
Krishna Institute of Medical Sciences Limited
758.35
74.30
10.86%
IN:METROPOLIS
Metropolis Healthcare Ltd.
552.85
134.15
32.04%
IN:SHALBY
Shalby Ltd.
167.60
-19.20
-10.28%

Artemis Medicare Services Ltd. Corporate Events

Artemis Medicare Announces Completion of Independent Director’s Tenure
May 10, 2026
Artemis Medicare Services Ltd. has announced that independent director Sunil Tandon has completed his tenure and ceased to be a director of the company as of May 9, 2026. The change is a routine board transition under SEBI listing regulations, ind...
Artemis Medicare Schedules Mumbai Investor and Analyst Meet for February 25
Feb 19, 2026
Artemis Medicare Services Ltd. has scheduled a physical investor and analyst meeting in Mumbai on February 25, 2026, comprising one-on-one and group interactions with a wide range of domestic institutional investors and advisory firms. The company...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: May 11, 2026